Related Experiment Videos
Summary
Primary malignant lymphomas of the breast are rare, accounting for 0.12% of breast tumors. Histiocytic lymphoma showed a better prognosis than undifferentiated types, with a 49% five-year survival rate.
Area of Science:
- Oncology
- Pathology
Background:
- Primary malignant lymphomas of the breast are rare, constituting only 0.12% of primary malignant breast tumors.
- These lymphomas are distinct from more common breast carcinomas, lacking clear distinguishing clinical features.
Purpose of the Study:
- To analyze the characteristics, treatment, and outcomes of primary malignant lymphomas of the breast.
- To compare the prognosis of different lymphoma subtypes in the breast.
Main Methods:
- Retrospective review of 14 cases of primary breast lymphoma diagnosed between 1944 and 1975 at M. D. Anderson Hospital.
- Analysis of patient demographics, tumor histology, treatment modalities (surgery, radiotherapy, chemotherapy), and survival data.
Main Results:
- All lymphomas exhibited a diffuse growth pattern. The subtypes included undifferentiated lymphoma (8 cases), histiocytic lymphoma (5 cases), and poorly differentiated lymphocytic, convoluted cell type (1 case).
- The overall five-year survival rate for 13 patients with follow-up was 49%. Patients with histiocytic lymphoma demonstrated a more favorable prognosis compared to those with undifferentiated lymphoma.
- Patients with undifferentiated lymphoma had a median survival of seven months, similar to American Burkitt's lymphoma. The patient with convoluted cell type developed acute blastic leukemia.
Conclusions:
- Primary breast lymphomas are uncommon malignancies with varied prognoses depending on histological subtype.
- Histiocytic lymphoma offers a better outlook than undifferentiated lymphoma, highlighting the importance of accurate subtyping for treatment and prognostic assessment.